RxDoctor Payments Data

John Thompson, MD

Nephrology · la Mesa, CANPI 1770663890

Payments from drug & device makers

$2,716in general payments, 2019–2025

Across 100 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$518
  • Mallinckrodt Enterprises LLC$322
  • OPKO Pharmaceuticals, LLC$262
  • Amgen$251
  • Otsuka America Pharmaceutical, Inc.$203
  • Fresenius USA Marketing, Inc.$188
  • plus $973 from 14 others

What the payments were for

  • Food & beverage$2,57495%
  • Education$1425%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,716 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$227,408
Medicare patients
333
Services billed
1,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol145$140,732
LokelmaSodium Zirconium Cyclosilicate17$15,342
Sevelamer Carbonate52$10,612
TradjentaLinagliptin11$10,604
JanuviaSitagliptin Phosphate12$7,428
Potassium Citrate ErPotassium Citrate31$2,026
Doxazosin Mesylate27$419
Losartan Potassium58$362
Tamsulosin Hcl28$325
Carvedilol34$298
Amlodipine Besylate83$291
Hydralazine Hcl21$276
Calcitriol20$266
Furosemide55$255
Atorvastatin Calcium17$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$518$156,074162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,341 nephrology providers in California.

Other nephrology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →